granulomatous inflammation. The only curative treatment is a hematopoietic stem cell transplantation (HSCT). In 2010, seven children from Sainte Justine hospital were included in an international initiative of HSCT for CGD, based on a reduced toxicity conditioning (RTC), followed by seven others transplanted after the completion of the study. Data were retrospectively extracted from medical charts for 14 consecutive children transplanted for CGD from 2010 to 2014. Donors were a matched sibling (3/14), or a matched unrelated donor (11/14). The RTC consisted of Fludarabine, targeted Busulfan and rabbit Antithymoglobulin or Alemtuzumab. The median age at HSCT was 15 years (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Previous history of severe infections included abscesses located in adenopathy (9/14), skin (8/14) , liver (7/14) or lungs (10/14), with pulmonary aspergillosis proven for five patients. Septicemia (4/14) and osteomyelitis (2/14) were also common. Inflammation mainly presented as Crohn like colitis (5/14) and chronic lung inflammation (6/14) . Three patients had received granulocytes transfusions previously. None patient had active infection or inflammation at the time of transplantation. All 14 patients engrafted. Severe (grade 3-4) acute graft versus host disease (GVHD) and chronic extensive GVHD were not observed. Three patients experienced immune haemolytic anemia (3/14) and nephrotic syndrome (1/14). The main complication was secondary graft failure for 3/14 patients occurring at 6 months. All three patients engrafted durably after a second HSCT. Including second grafts, post 6 months after HSCT, chimerism was higher than 90 % in 13/14 patients and 66 % in one patient. With a median follow-up of 43 months , all patients are alive, cured from CGD and free from immunosuppressive drugs. HSCT with a RTC and a matched unrelated donor is safe and effective for children with severe forms of CGD. Background: IgE is critical for allergen-mediated inflammation. IgE is expressed by memory B cells (MBC) and plasmablast (PPC) intermediates, which differentiate into IgE-producing plasma cells (PC). Allergen exposure has been shown to increase IgE levels in the airways of allergic asthmatics; however, B cell subsets expressing and producing IgE in the airways has yet to be studied. Methods: Allergic asthmatics (AA), allergic non-asthmatics (ANA) and healthy controls (HC) were recruited to donate blood and sputum samples. Peripheral blood mononuclear cells (PBMCs) were separated using density gradient centrifugation, and stained with CD19, CD27, CD38, CD45, CD138, IgG and IgE antibodies with appropriate isotype controls. Sputum was induced by inhalation of 3, 4 and 5 % hypertonic saline, and sputum cells were isolated and stained with CD19, CD45, IgE and IgG. Cells were acquired using a Becton-Dickinson LSRII flow cytometer, analyzed using FlowJo and data were expressed as mean ± SEM. Lymphocytes were defined as SSC low CD45+, and B cells were defined as SSC low CD45+CD19+. GraphPad Prism was used to perform one-way ANOVAs and Tukey post hoc analyses. Results: Circulating levels of B cells and IgE-expressing B cell subsets, including MBCs (CD27+CD38−), PPCs (CD27+CD38+) and PCs (CD38+CD138+) were similar in percentages and absolute numbers between AA, ANA and NC. In contrast, the level of IgE-expressing B Table 2 Comparing the percentages and absolute numbers of regulatory B cells in the airways of allergic asthmatics, allergic non-asthmatics and healthy controls * p < 0.05 compared across subject groups 0.00013 ± 0.00005 0.00018 ± 0.00007 0.00004 ± 0.00003 cells in sputum was higher in AA compared to ANA and HC, and this was evident when cells were expressed as percentages or as absolute numbers (p < 0.05, Table 3 ).
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Outcomes of patients with severe combined immunodeficiency (SCID) prior to and after initiation of newborn screening for SCID in Ontario
Conclusions:
Compared to allergic non-asthmatic subjects and healthy controls, subjects with allergic asthma demonstrated higher levels of IgE-expressing B cells in their airways, but not blood. This suggests localization of IgE-expressing B cells in the airways of allergic asthmatics, where local production of IgE in the airways may be important in the pathogenesis of allergic asthma. Background: Primary immunodeficiency disorder (PID) refers to a heterogeneous group of disorders characterized by poor or absent function in one or more components of the immune system. More than 250 different disorders have been identified to date, with new disorders continually being recognized [1] .Treatment in PID patients has reduced the mortality and morbidity. Thus, such patients often survive into adulthood. [2, 3] Although it is likely that more women with PID will wish to become pregnant in the future, only a few such cases have been reported to date. In this article PID pregnant cases and their management has been evaluated.
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Methods:
The PID cases that became pregnant have evaluated and followed in PID clinic, Isfahan University of Medical sciences between 1997 and 2014. Depend on variety of immunodeficiency, supportive and definitive treatment has been done for pregnant patients. Result: Two patients had pregnancy and were followed and managed. A CGD patient with history of recurrent infections such as empyema, pneumonia, TB lymphadenitis, cutaneous abscess, mouth ulcer and gingivitis whose pregnancy course was uneventful. After normal vaginal delivery, she faced to severe low back pain, sacral fungal osteomyelitis and granulomatous lesion all over her uterus and liver who has been treated with antifungal and interferon gamma. Another PID case with CVID and history of upper and lower respiratory tract infections and thrombocytopenia who has been managed during her pregnancy period and delivery for severe thrombocytopenia by higher dose of IVIG and even platelet infusion during her cesarean section.
Conclusion:
The treatment of PIDs is complex and generally requires both supportive and definitive strategies. The pregnancy potentially is high risk and immune regulation switch may provide more complication and disorders during pregnancy. According to the type of PID, management and treatment of PID patients could be different and future researchers in this area have to be done. A total of 135 patients were treated with Octagam ® 10 % for 28 different conditions represented by five distinct indication groups: immunology (43 %), hematology (28 %), neurology (17 %), rheumatology (5 %), and infectious disease (3 %). Ontario Regional Blood Coordinating Network (ORBCoN) recently published an audit of the routine clinical use of IVIg products across Ontario [1] . The audit included 2246 patients over a 3-month period representing 120 indications. The audit captured labeled versus unlabeled utilization. Labeled indications referred to those that were approved for use by Health Canada for at least one IVIg product. The off-label utilization was categorized as off-label and potentially indicated, or off-label and not indicated. Applying the same criteria set forth in the ORBCoN audit, each of the indications identified in this study were similarly classified (Fig. 1) . The results of this retrospective chart review indicate that Octagam ® 10 % is prescribed to Canadian patients similar to other IVIg products, with 85 % of the utilization deemed appropriate based on current IVIg Background: Kounis syndrome is a rare but increasingly recognized clinical entity whereby anaphylactic or anaphylactoid reactions provoke coronary artery spasm that may lead to acute myocardial infarction. The pathogenesis is thought to be secondary to mast cell activation-degranulation [1] . A "Kounis-like" syndrome has been described in two patients with mast cell activation disorders presenting with neurologic symptoms yet no evidence of stroke on extensive imaging [2] . Case presentation: A 62-year-old male with a history of dyslipidemia and hypothyroidism presented with a three-day history of nausea, vomiting, fevers, and abdominal pain. There were no complaints of chest pain or shortness of breath. Background: Bumble bee allergy is an uncommon cause of Hymenoptera venom allergy. Studies have suggested a variable degree of immunological cross reactivity between bumble bee and honeybee venoms [1] . Bumble bee venom is not available for skin testing in Canada.Treating bumble bee allergic patients with honeybee venom immunotherapy has been described in the literature [2] . We present a case of unsuccessful honey bee immunotherapy in a patient with a previous anaphylactic reaction to eastern North American bumble bee, Bombus impatiens. Case presentation: A 32 year old laboratory worker with bumble bees had a number of stings over years without reaction. In 2009 he had three stings within a few months and developed hypotension, generalized urticaria and wheezing immediately after the third sting. Serum IgE levels were markedly elevated for both honey bee and bumble bee and he was commenced on honey bee immunotherapy at another centre, being maintained on 100 mcg monthly injections for 5 years with total compliance. He was not stung over this period. On subsequent evaluation he was negative to intradermal testing (0.02 mL) with honey bee venom at 1 mcg/mL. A sting challenge to western bumble bee (Bombus occidentalis) was done and the patient developed immediate anaphylaxis symptoms and required treatment with epinephrine and antihistamine. Conclusions: Without access to IgE testing to specific antigens contained in various Apidae species, cross-reactivity canntot be determined. Immunotheapy with honey bee venom did not protect our patient with bumble bee allergy. Bumble bee venom immunotherapy has been reported in Europe but European species vary significantly from North American species. Our experience suggest significant similarity in allergen content between eastern and western bumble bee venoms. With incresing use of bumble bees in agriculture, allergic reactions to stings may become more prevalent and access to venoms for testing and immunotherapy more important. Consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Case report: We report a 7-year-old patient with persistant and refractory auto-immune complications post-hematological stem cell transplantation (HSCT). He was diagnosed at 3 years of age with a leaky SCID (homozygous mutations of RAG1) after several auto-immune complications and repeated infections. He underwent a mismatched umbilical cord blood transplantation (5/6) at 40 months with a conditioning regimen of Busulfan, Cyclophosphamide and rabbit ATG. His hematological reconstitution was good and he was platelet transfusion-free by day 59 post-HSCT. Chimerism stayed 100 % donor from day 100 post-HSCT. He presented severe acute and chronic GvHD adequately controlled with heavy immunosuppression until 2 years post HSCT. Two and half years post-HSCT, he presented with profound peripheral pancytopenia. As this pancytopenia was resistant to Prednisone, immunoglobulins and rituximab, he received two injections of Alemtuzumab. While red and white blood cells recovered completely, he presented a persistant and refractory immune thrombopenia (ITP) despite treatment with prednisone, sirolimus, Rituximab, and two courses of bortezomib. A splenectomy was performed with transient efficacy, and romiplostim was added to his treatment shortly after. Concurrently, our patient had very poor immune reconstitution. His CD4+T lymphocytes stayed inferior to 200/µl and the emigrant thymic naive T cells (CD45RA+CD31+/CD4 cells) were nonexistent. As the thymic function seemed to be absent, thymic transplantation was discussed. However, with the combination of splenectomy and romiplostim as platelet-enhancing therapies, we were able to progressively wean prednisone therapy down to a minimal dose of 0.3 mg/kg/day with subsequent restoration of thymic function, as shown by uptrending of CD4+ T lymphocytes and emigrant thymic naive T cells, with latest values of 561/µl and 38 % respectively. Consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Background: Acquired angioedema is an acquired form of C1 deficiency, where inappropriate bradykinin release can result in skin swelling (face and limbs), severe abdominal pain from gastrointestinal mucosal edema and life-threatening upper airway swelling. It has been reported in patients with lymphoproliferative disorders. Autoantibodies to C1 inhibitor are present in many of these individuals. Clinical presentation: Three cases of acquired angioedema are presented. All three individuals presented over several years with recurrent episodes of angioedema and eventually, required ICU admission and intubation for airway angioedema. Their lab work demonstrated low C4 and C1 inhibitor levels. Given later onset of symptoms and lack of family history, they were diagnosed with acquired angioedema. The C1q assay was not readily available to confirm the diagnoses. Case 1, a 76 year old female, had an abnormal peripheral smear, SPEP and bone marrow aspirate suggestive her angioedema was secondary to a lymphoproliferative process. Case 2, a 77 year old male later developed colon cancer but his angioedema did not improve with cancer treatment, so the two were felt to be unrelated. Case 3, currently a 56 year old male presented in his early 50s. He underwent gene testing for hereditary angioedema which was negative. His laboratory tests revealed a small monoclonal band on serum protein electrophoresis. Management and outcomes: The first two patients were treated with danazol prophylaxis. One case had fluctuating levels of C1inh and C4 that did not correlate with danazol dosage or symptoms. Danazol for both cases was titrated to symptoms and maintained at an average dose of 200 mg per day. The third case had limited clinical response to various doses of danazol and initially required scheduled C1 inhibitor replacement. Eventually, he was treated with tranexamic acid for prophylaxis. He has been well controlled with tranexamic acid 1500 mg TID. Consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Background: There are limited reports linking the dipeptidyl peptidase-IV (DPP-IV) inhibitor sitagliptin with upper airway angioedema. Most reports thus far suggest an interaction with the concurrent use of an angiotensin II receptor blocker (ARB) or an angiotensin-convertingenzyme (ACE) inhibitor. The proposed mechanism is shared inhibition of the bradykinin degradation pathway by ACE or DPP-IV inhibitor, or increased effect of bradykinin while on ARB. Case: In March 2015, a 100 pack year former smoker was referred to our Adverse Reactions Clinic for recurrent episodes of lip, tongue, and throat swelling. These episodes occurred 3-4 times a month for several years, with numerous emergency department visits. Our patient had been on prednisone 5 mg daily for several years to manage these episodes, increasing to 40 mg during an exacerbation. They previously had angioedema while taking an ACE inhibitor and possibly following aspirin. They also had seasonal allergies, a rash with amoxicillin, and GI upset with glyburide. They managed their diabetes with insulin. Their other medications included sitagliptin/metformin (Janumet Course: We advised our patient to discontinue sitagliptin and take metformin alone. They have had no further emergency department visits for angioedema. Discussion: Sitagliptin, like ACE inhibitors but not to the same extent, may prevent the breakdown of bradykinin. ACE inhibitors are also much more likely to cause swelling than ARBs. Although ARBs do not inhibit the breakdown of bradykinin, they block bradykinin two receptors and make more available to cause swelling. It is thus possible that sitagliptin played a role in this patient's recurrent episodes of angioedema, especially given the onset of the symptoms after the initiation of the drug ten years ago, the disappearance of symptoms with its discontinuation, and the similar previous problems with ACE inhibitors. Our patient had Allergy Asthma Clin Immunol 2016, 12(Suppl 1):22 several risk factors that would increase her risk of angioedema while on ACE inhibitors (and potentially DPP-IV inhibitors). Generally, risk factors associated with ACE inhibitor-induced angioedema include previous or current smoking, female gender, seasonal allergies, and "African American race", while having diabetes is protective (as reported in the Omapatrilat Cardiovascular Treatment versus Enalapril [OCTAVE] study). Her presentation was typical of bradykinin-dependent angioedema, namely, swelling lasting several days, without pruritus or urticaria, and being somewhat refractory to corticosteroids. Background: Subcorneal pustular dermatosis (SCPD) is a rare benign chronic inflammatory skin disorder of unknown etiology. First described by Sneddon and Wilkinson in 1956, it is characterized by a relapsing course of symmetric subcorneal sterile pustules involving the flexures, proximal limbs, and trunk. SCPD is often associated with a benign monoclonal IgA gammopathy, which can either precede or follow diagnosis. [1] . Case: A 56-year old Caucasian female presented to our outpatient immunology-dermatology clinic with a seven-year relapsing history of a mildly pruritic and irritating pustular skin eruption under the arms, breasts, and around the groin. Physical examination showed several pea-sized flaccid pustules on an erythematous base in the axillae, groin, and submammary regions (Fig. 2) . The patient was otherwise well with no signs of systemic disease.
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Investigations:
Routine blood work including a complete blood count and liver function tests were normal. Serum protein electrophoresis showed an abnormal IgA monoclonal gammopathy lambda type with a value of 4.63 g/l (normal 0.7-3.52 g/l). Histopathology showed a sterile subcorneal pustule with inflammatory infiltrate of lymphocytes and neutrophils with the absence of acantholysis. Her previous treatments included topical corticosteroids and antibiotics as well as oral cephalexin and itraconazole, all with poor response. Discussion: The main differential diagnosis of SCPD includes pustular psoriasis, pemphigus foliaceus, IgA pemphigus, impetigo, dermatitis herpetiformis, and acute generalized exanthematous pustulosis. Our patient had been previously treated with antibiotic and antifungal agents with poor response for an infectious cause of the disease. Clinicians may consider an inflammatory disease in their differential when presented with a pustular eruption in the interigenous areas. Consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Background: Allergic bronchopulmonary aspergillosis (ABPA) is a challenging respiratory disease with significant morbidity and mortality. Among patients with severe asthma, 10 % have ABPA. Typically they have a decline in lung function, positive skin prick reaction to Aspergillus, elevated IgE levels, increased Aspergillus fumigatus specific IgE antibody and central bronchiectasis. Patients often exhibit refractory symptoms despite conventional asthma therapy. Longterm use of high dose inhaled and oral corticosteroids may lead to serious adverse effects such as immunosuppression, adrenal insufficiency, metabolic syndrome, hypokalemia, glaucoma, cataracts, peptic ulcers, osteoporosis, avascular necrosis, and psychiatric disturbances. Antifungals have many drug interactions and may require therapeutic monitoring. Some studies seem to suggest that omalizumab may be a better therapeutic option as there is some evidence demonstrating efficacy in ABPA and fewer adverse effects than long-term corticosteroids. Methods: A retrospective chart review was performed for ABPA patients receiving omalizumab between 2007 and 2015 at our tertiary care Allergy and Asthma Clinic and The Ottawa Hospital Chest Clinic. Data was collected on demographics, total IgE, aspergillus specific skin testing, the use of inhaled and oral corticosteroids, quality of life (QoL) questionnaires, and number of asthma exacerbations/hospitalizations. Results: A total of ten patients were evaluated (59.7 ± 13.9 years, 7 females and 3 males). Compared to their baseline, the average dose of inhaled corticosteroids dropped by 24 % at month 16 and out of the three patients who were dependent on oral corticosteroids, there was an 89 % decrease in prednisone use by month 16. QoL scores improved in relation to baseline. Nine of the subjects that reported exacerbations 12 months prior to treatment and none reported exacerbations once they started omalizumab. 
Conclusion:
Our retrospective study provides evidence to support the fact that omalizumab may be an effective low-risk treatment for patients with ABPA. Further prospective studies are required to confirm this finding. Consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Background: Cystic fibrosis (CF) is an autosomal recessive disease associated with airway obstruction and chronic lung infections. Allergic bronchopulmonary aspergillosis (ABPA) complicates 7-9 % of CF cases. The first-line therapies for treating ABPA are corticosteroids and antifungal drugs. Long-term use of corticosteroids may result in very serious adverse effects such as immunosuppression, adrenal insufficiency, and diabetes. Antifungals, mucolytics, pancreatic enzymes and bronchodilators are also other treatment modalities. A few studies suggest omalizumab may be effective in CF. Here we report a 25-year old male CF patient with concomitant ABPA complicated with numerous hospitalizations and steroid side effects who responded well to omalizumab. Methods: A retrospective chart review was performed. Evaluation jointly occurred at The Ottawa Hospital's CF Clinic and a tertiary care Allergy and Asthma Clinic in Ottawa.
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Efficacious use of omalizumab in the treatment of cystic fibrosis
Results:
The patient was diagnosed with CF at 5 months old. This patient had a positive skin prick reaction to Aspergillus fumigatus and a total serum IgE of 111.7 IU/mL. He developed corticosteroid-induced diabetes at age 19. Given his poor health and high IgE levels, a decision was made to attempt a trial of omalizumab. After 8 months of omalizumab, he successfully weaned off of prednisone. After 18 months, the patient no longer required insulin to treat his prednisone-induced diabetes. After 20 months, his quality of life improved. During the 12 months prior to treatment he was hospitalized 8 times. He had only one hospitalization since month seven. He was considered for a double lung transplant, but after 1 year of treatment, transplantation was no longer for consideration because he stopped needing daily home oxygen. Conclusion: Omalizumab had a dramatic steroid sparing effect, reduced hospitalizations and O 2 requirements in this CF patient with ABPA and prednisone-induced diabetes. Further prospective studies using a larger cohort are necessary to make any clinical recommendations. Consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Background: Hereditary angioedema (HAE) with normal C1-esterase inhibitor (C1-INH) is subdivided into factor XII mutation or of unknown origin (U-HAE). The diagnosis is based on clinical symptoms of recurrent edema (commonly skin swellings, tongue swelling), family history, and normal C1-INH quantity and function. U-HAE is presumed when factor XII mutation testing is negative. Here we present a 65 year old male with suspected U-HAE, who has a 30-year personal history of recurrent upper airway swelling, family history, and normal C1-INH quantity and function. He initially responds to empiric C1-INH. However, he seems to have developed resistance to C1-INH, requiring rescue therapy with icatibant. Methods: For each treatment, a log method was used to collect information on: attack intensity, anatomical location, number of doses, onset of relief, time elapsed until complete resolution. Hospital records and patient-reports were collected for each treatment received through the emergency department. Results: This patient was first seen September 2013 for suspected HAE. C4 and C1 INH quantities and function were repeatedly normal. In October 2013, the patient began IV treatment with CI-INH for the first time with good response. In June and October 2014, treatment with multiple doses of C1-INH was required to achieve resolution of symptoms. In February 2015, despite multiple C1-INH doses, the patient was intubated and admitted to ICU for tongue swelling with throat involvement, which resolved slowly over 4 days. In April 2015, icatibant was used for treatment in the ED when on tongue swelling occurred and was unresponsive to C1-INH. Swelling began to subside within 1 h of the icatibant administration. Since then, the patient has had many documented swellings that have not responded to C1 but have responded to icatibant. Conclusion: Icatibant can be an effective treatment for suspected U-HAE when treatment response with intravenous C1 esterase inhibitor is inadequate. Consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Background: Lactose intolerance affects approximately 20 % of Canadians and roughly 70 % of the world's population, leading to symptoms of flatulence and bloating after the ingestion of lactosecontaining foods. Lactose intolerance develops primarily due to the absence of the enzyme lactase and can occur in childhood or adulthood. Treatment involves ingestion of commercially-available lactase enzyme preparations often produced by Aspergillus bacteria [1, 2] . Although anaphylactic reactions involving IgE mediated hypersensitivity have been reported for a number of foods, this case report represents the first documented evidence of anaphylaxis after exposure to supplemental lactase enzyme preparation. Case report: A 38 year old white female teacher presented with a history of adult-onset lactose intolerance and a suspected allergy to lactase tablets after an episode of bilateral orbital swelling, shortness of breath, and throat constriction that responded to diphenhydramine. The patient's past medical history included oral allergy syndrome and medication-controlled asthma. She handled lactase tablets for years due to her children being lactose intolerant but only recently began using the tablets herself. Physical examination was benign, and skin prick testing to a slurry of the lactase tablet revealed a strongly positive reaction wheal size of 10 mm and flare of 60 mm with normal controls (Fig. 3) . The patient required cetirizine treatment in clinic. Skin testing was performed with individual ingredients of the lactase tablet provided by the manufacturer and Aspergillus niger, a common bacteria used in lactase preparations. Only concentrated lactase enzyme elicited a positive response. Avoidance of lactase tablets was advised and the patient was educated in the use of injectable epinephrine. Conclusion: This is the first documented case report of an anaphylactic reaction to lactase enzyme. The patient experienced systemic symptoms including shortness of breath and orbital swelling, reinforcing the importance of education and avoidance of triggers in these rare circumstances. Disclosures: None. Background: Primary immune deficiency (PID) is a major risk factor for the development of malignancy in both the pediatric and adult patient population. It is a major cause of morbidity and mortality, coming second only after infection as the leading cause of death. To date, lymphoreticular malignancies are cited as the most common type of malignancy known to affect people with PID. Little is known about the risk of solid tumor malignancies in this population. Methods: A literature review and a retrospective chart review of 400 adult patients at a local private practice was undertaken. Patients were selected if they both met a diagnosis of primary immune deficiency and solid tumor malignancy. Solid tumor malignancy was defined as a malignancy that was neither lymphoma nor leukemia. Results: Two patients met the criteria of PID and solid tumor malignancy. The first was a male with X-linked agammaglobulinemia (XLA) who developed colorectal cancer and the other patient was a female with Common Variable Immune Deficiency (CVID) who was diagnosed with pancreatic cancer.
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Risk of solid tumor malignancies in patients with primary immune deficiency
Conclusion:
There are only a few studies in the literature regarding the incidence of solid tumor malignancies and PID. These two cases add additional evidence that patients with PID may not only be at risk for lymphoproliferative tumors but perhaps of solid tumors as well. The diagnosis of PID should alert the clinician to this potential relationship and ensure patients with PID undergo age appropriate primary prevention strategies. Additional studies are required to validate these conclusions.
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Is it time to adopt the chromogenic assay for measuring C1 esterase inhibitor function in patients with HAE type 2? Elizabeth Yeboah Background: Type II HAE is characterized by functional deficit in C1 inhibitor (C1 INH). C1 INH function can be assessed by radial immunodiffusion (RID), ELISA or a chromogenic assay [1] . We present our institution's experience with a type II HAE patient, whose disease was initially undetected by radial immunodiffusion. Case presentation: A 62-year-old female was referred to the Clinical Immunology Clinic, McMaster University for assessment of type II HAE. This diagnosis was made two decades prior when she had recurrent abdominal pain and a functional C1 INH deficit detected at a US laboratory. She had no history of facial, extremity or airway angioedema. She was previously managed with danazol prophylaxis, which was discontinued 15 years prior, and had never required C1 INH infusions. There was no family history of HAE. Co-morbidities included allergic rhinitis. Seven months after consultation, while travelling abroad, she experienced a typical HAE flare with facial and airway swelling. She was managed effectively with repeated frozen plasma transfusions. Danazol prophylaxis was restarted. Upon return to Canada, she had three additional flares, managed with C1 INH infusions or icatibant. Her HAE diagnosis was re-evaluated repeatedly (Table 4 ). C4 levels were consistently low while C1 INH levels were high. Functional assay was normal twice, abnormal once and then normal again, as measured by radial immunodiffusion at the Clinical Chemistry and Immunology Laboratory, Hamilton Health Sciences. For her most recent evaluation, C1 INH function was concurrently measured by the chromogenic assay at CHU Sainte-Justine, Montreal, QC and found to be low. Conclusions: A recent paper [1] suggests the chromogenic assay is more sensitive for diagnosing C1 INH dysfunction. This case Results: About 1 % of total ED visits were for anaphylaxis or allergic reaction. Children and residents of rural areas were over-represented. Most visits occurred in the summer months. Since 2006-07, the rate of all allergy-related ED visits increased by 6 %, with increases particularly high for children under 18 (29 %) and for anaphylaxis-specific visits (80 %). At the same time, epinephrine auto-injector prescriptions increased by 64 %, again particularly among children. Conclusions: While overall anaphylaxis and allergy rates remained stable at 1 %, the proportion of visits specifically for anaphylaxis increased significantly over time. In addition, an increased number of children are receiving prescriptions for epinephrine auto-injectors. Given the small increase in overall allergy-related visits, this may reflect a growing awareness of allergies in Canada and changes in coding practices. ED visits remain uncommon and rates of epinephrine auto-injector prescriptions are well below the estimated 7 % of Canadians with allergies. 
Conclusion:
The higher concordance rate in DZ twins for peanut allergy suggests that non-genetic factors play a major role in the pathogenesis of peanut allergy. The small sample size renders our comparisons for tree nuts inconclusive. Comparisons for egg, milk, shellfish, and fish were not performed due to an insufficient sample.
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Qualifying the diagnostic approach employed by allergists when managing patients with self-diagnosed non-celiac gluten sensitivity (NCGS) Lee Horgan Background: Non-celiac gluten/wheat sensitivity (NCGS) is an emerging entity in the medical literature and lay press. Characterized by nonspecific gastrointestinal symptoms that improve with gluten restriction, it often remains a self-reported illness [1] . This population represents a common and often challenging clinical encounter for practicing allergists. Method: Canadian allergists were identified using publically available physician registries maintained by each province's College of Physicians and Surgeons. A letter of information was faxed to eligible participants and interested parties were invited to complete a brief, semi-structured telephone interview discussing their clinical approach to NCGS. Preliminary Results: A letter of information was faxed to the office of 55 Canadian allergists. At the time of abstract submission, two interviews were completed and three were scheduled for a later date. One respondent declined participation. Of the completed interviews, 50 % of participants were female with an average participant age of 36 years and an average time in practice of 27 months. Both respondents endorsed routine use of wheat allergy skin testing but varied in their use of Celiac Disease serology. One endorsed routine referral to gastroenterology for consideration of endoscopy. Follow-up practices also varied with one participant endorsing routine follow up at six months and the other offering follow-up quite infrequently. Conclusions: Our desired sample size of 15-20 participants will allow us to document the Canadian allergist approach to NCGS. We intend to use this data to develop clinical care guidelines for NCGS in collaboration with our Canadian allergist colleagues. Background: Hypersensitivity to the staple foods, milk, egg and wheat, has been described through childhood. We aimed to describe staple food hypersensitivity (sFHS), including symptoms and sensitisation by allergen-specific Immunoglobulin E (IgE) in a population-based birth cohort of Swedish children born in 1994-96 and followed to 16 years. Methods: Using questionnaire and clinical data, we defined sFHS by 2 years of age, between 2-4 years of age and at 16 years of age. Symptoms included vomiting, diarrhoea, eczema/rash, itch, angioedema, rhinitis and/or asthma after staple food consumption. At 1, 2, 4, and 16 years, parent-reported doctor's diagnosis of food allergy was ascertained. In a subgroup, sera obtained at 4 and 16 years were analysed for IgE to common food allergens (including staple foods) via fx5 ® . IgE reactivity to any or all staple foods was defined as IgE ≥ 0.35 kU A /l. From these data, we created three definitions: A: Symptoms only (N = 2386) ; B: Symptoms + doctor-diagnosed food allergy (N = 2386), and; C: Symptoms + IgE reactivity (N = 1493). Persistent sFHS was defined as sFHS by 2 years of age and/or between 2-4 years, and at 16 years. Descriptive statistics were used to establish prevalences and to test for differences. Results: For definitions A and B, the prevalence of sFHS remained stable from 2 years, to 2-4 years, but increased significantly to 16 years (A: 6.3, 4.9, 7.2 %, respectively, p < 0.001; B: 3.7, 2.4, 6.3 %, respectively, p < 0.001). For definition C, the prevalence of sFHS at 4 and 16 years was 4.2 and 2.7 %, respectively (p < 0.04). All children with persistent sFHS, regardless of definition, had symptoms, including more severe symptoms, compared to significantly fewer children with the same definition of sFHS at 16 years only (e.g. Background: Our previous work identified gaps in confidence for administering epinephrine autoinjectors among parents and children. The aim of this study is to further describe the impact of supervised autoinjector administration by parents/patients on confidence, knowledge and skill for future treatment of severe allergic reactions. Methods: Patients aged 2-17 years with confirmed IgE-mediated food allergy at BC Children's Hospital (2013-15) undergoing a physician supervised oral food challenge were recruited. A pre-challenge questionnaire validated by expert panel on patient and caregiver background information and self-assessed confidence (five point scale) in the ability to recognize and treat a severe allergic reaction was completed by each participant. If an autoinjector was deployed during the challenge, a similar questionnaire was administered. Since data was not normally distributed, Mann-Whitney U and Wilcoxon signed rank tests were used to test differences between groups. Results: Among caregivers who never previously deployed an epinephrine autoinjector, 67/104 (66 %) experienced at least one severe allergic reaction within the family, and 25/104 (24 %) had experienced three or more severe reactions. Pre-challenge median scores for recognition of a severe reaction, confidence in autoinjector administration, knowledge of technique, and autoinjector skill were 4(IQR = 1), 3(IQR = 1), 4(IQR = 2), 3(IQR = 2). Further descriptive statistics are in Table 5 . Parents who were health professionals perceived themselves to be more confident in all domains (median difference of 1 for each, p < 0.05) compared to non-health professionals. Post-challenge confidence in autoinjector administration and skill among those receiving epinephrine increased by a median of 1 and 2 respectively (p < 0.05). Conclusions: Although participants described reasonable knowledge of recognition and technique, confidence and skill for autoinjector use were suboptimal. In those who used the autoinjector during an oral challenge, perceived confidence in administration and skill levels increased. This suggests potential educational benefit of supervised epinephrine self-treatment, since many who have never used an epinephrine autoinjector have experienced severe allergic reactions.
A25
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Local immunoglobulin production to Aspergillus fumigatus cystic fibrosis Jonathan Argeny
Background: Cystic fibroses (CF) is an autosomal recessive multisystemical disorder that is characterized by a progressive neutrophildominated inflammation of the lungs and their colonization by typical bacteria. Patients suffering from CF are very often sensitized to Aspergillus fumigatus (Asp fum), an ubiquitously occuring fungus. In some cases, this can lead to the disease so called, allergic bronchopulmonary aspergillosis (ABPA). We aimed to investigate whether local antibodies against Asp fum (IgG, IgA, IgE) in the lungs of children and adolescents with CF are detectable and if there is a correlation with reduced lung function. Methods: BALF samples of children with CF (n = 49) and a matched control group (n = 12) were obtained by bronchoscopy and clinically relevant parameters [lung function, BMI, age, Pseudomonas aeruginosa (PA) colonization] were assessed. Asp fum -specific IgE was measured in serum using ImmunoCAP and Aspergillus-specific antibodies of different Immunoglobulin subclasses (IgG, IgA, IgE) were quantified in BALF using an "in house" ELISA. Results: Local immunoglobulin production against Asp fum was observed in more than 80 % of CF patients compared to the control group. Specific AF-BAL IgE and systemic specific IgE did not correlate with each other in patients with CF (r = 0.26; p = 0.075). CF-patients with Asp fum in BALF had significantly increased Asp fum-IgG and Asp fum-IgA as compared to patients with no Asp fum detectable in BALF. Patients with Asp fum-IgE in BALF displayed a higher forced vital capacity as compared to patients with systemic and local IgE. Conclusions: We provide evidence for local IgE production to AF in patients with CF. Local IgE may precede systemic Asp fum-Ige production or even have protective effects.
A29
Extract consumption with skin prick test (SPT) devices
Greg. Plunkett Background: Allergy skin prick testing involves introducing a small amount of allergen extract percutaneously using pointed devices. The current standard of care involves placing a drop of extract (40 μL) on the skin and then puncturing the skin through the drop via a prick lancet. Alternative methods include dipping sterile devices into extract and then pressing the device onto the skin. The objective of this study was to determine the amount of extract used for four devices at different tube/well fill volumes. Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are very commonly used drugs worldwide, constituting the second major cause of hypersensitivity reactions after beta lactam antibiotics. The study's aim was to evaluate clinical and demographic data of patients referred to our hospital with suspected hypersensitivity to NSAIDs. Method: All cases with NSAID reaction history admitted to our pediatric allergy department between February 2013-2015 were included in our study. Case data was compiled by ENDA questionnaires and faceto-face interviews with parents. Skin tests and/or oral provocation tests (OPT) were performed with NSAIDs according to guidelines, after obtaining written informed parental consent. Results: 50 cases (40 % male, 60 % female; mean age 7.36 ± 4.72 years) were included. Two patients (4 %) had asthma, rhinosinusitis, and nasal polyps, while six (12 %) had allergic underlying diseases-atopic dermatitis/asthma/allergic rhinitis. The drugs considered to have caused the symptoms were acetaminophen in 18 (36 %) cases, ibuprofen in 17 (34 %), acetaminophen and ibuprofen in 11 (22 %), acetylsalicylic acid (ASA) in 2 (4 %), naproxen in 1 (2 %), and acetaminophen, naproxen and ASA in one (2 %). Background: With the burden of allergic disease increasing worldwide [1] , prolonged wait times are a significant concern. Published reviews of referral patterns have focused on adult populations and do not report final diagnoses [2, 3] . This is the first study that we are aware of to compare reasons for referral with final diagnoses from a pediatric allergy clinic. Methods: A review of first presentations to the BC Children's Hospital Allergy clinic is currently underway. Data on age, gender, referral source, reason for referral, and final diagnoses were recorded. Descriptive statistics were used to characterize reasons for referral and final diagnoses. Results: Among 68 referrals reviewed to date, 78 % were from general practitioners, while 22 % came from specialists. Median patient age was 4 years (IQR4), and 51 % were female. Most had a single reason for referral (84 %). Table 7 shows referral indications and final diagnoses. Food allergy was the most common reason for referral (71 %), followed by allergic rhinoconjunctivitis (22 %), asthma (10 %), drug allergy (7 %), parent request (1 %), and laboratory result (1 %). Multiple diagnoses were assigned in 10 %. Food allergy was the most common final diagnosis (35 %), followed by allergic rhinoconjunctivitis (24 %), asthma (4 %), drug allergy (1 %) and food protein induced enterocolitis (1 %). Among those referred for suspected food allergy, only 50 % had a final diagnosis of food allergy. Nearly half (44 %) of all referrals received a non-allergic diagnosis. Conclusions: We report a higher proportion of referrals for food allergy (71 %) than seen in prior reports from mixed adult/pediatric practices (19-24 %) [2, 3] . Only half of the patients referred for food allergy received a confirmed diagnosis, suggesting many may not have required referral. Greater efforts to educate parents and referring physicians about when to truly suspect a food allergy and the pitfalls of food allergy testing are warranted.
A32
Internist referral practices for inpatients with self-reported penicillin allergies at a tertiary care teaching hospital Michael N. Background: Unverified, self-reported penicillin allergy is a common clinical problem among hospitalized patients. These patients often receive broader spectrum, more expensive, and often inferior antibiotics secondary to their unverified penicillin allergy. The large majority of patients with self-reported allergy to penicillin do not have a true type-I mediated penicillin allergy and could benefit from de-labelling. Methods: We conducted a retrospective cohort study of 575 consecutive patients admitted to the internal medicine ward at the Montreal General Hospital between April 1st, 2014 and September 9th, 2014. Each patient's electronic chart was reviewed for documentation of reported penicillin allergy. For patients with reported penicillin allergy, their full chart was reviewed to determine what their documented drug reaction was, if they had received antibiotics during their admission, the indication for antibiotic use, antibiotics received, and presence or absence of inpatient or outpatient allergy consultation for evaluation. Results: A total of 74 patients out of the 575 total admissions during the study period reported a penicillin allergy, with a prevalence of 12.9 %. Forty patients (54 %) with an unverified penicillin allergy received antibiotics during their hospitalization. The most common antibiotics prescribed to these patients were moxifloxacin, ciprofloxacin, ceftriaxone, and vancomycin. The most common allergic reaction listed in the electronic medical record was unknown (46 %). Only four patients (5.4 %) received inpatient consultation with an allergist and all of these patients were thought to have suffered an allergic reaction during their hospitalization. There were zero outpatient referrals made for hospitalized patients with a history of unverified penicillin allergy. Conclusion: Referral rates for penicillin allergy evaluation continue to be extremely low-5.4 % in our study. Given the potential impact de-labelling programs may have on antibiotic utilization and stewardship, educational programs and de-labelling projects are currently being explored. Background: Graded drug challenge is used to determine amoxicillin allergy. However, the risk of future reaction upon subsequent treatment in those with a negative challenge is currently unknown. We aimed to assess the risk of amoxicillin hypersensitivity upon subsequent use in children referred due to suspected amoxicillin allergy who had a negative graded oral challenge. Methods: All children referred to the Montreal Children's Hospital for potential antibiotic allergy were recruited for the study between March 2013 and 2015. A standardized survey with questions on treatment, symptoms, and possible associated factors was filled out and an oral challenge (10 and 90 % of the oral dose) was conducted at the clinic visit. Six months after the challenge and every 6 months thereafter, the patients were contacted by phone to be asked questions on subsequent antibiotic use and associated reactions. Results: Among 366 patients with a negative oral challenge eligible for a follow-up, 250 (68.3 %) patients responded. Of the contacted patients, 60 (24.0 %) reported amoxicillin use and 7 [11.7 % (95 % CI 5.2, 23.2 %)] patients reacted to a subsequent treatment. Amoxicillin was primarily used to treat acute otitis media (AOM). Of those seven patients that did not tolerate the amoxicillin, 57.1 % were male with a median age of 0.9 years (IQR 0.5, 3.9) at the time of reaction and 2.1 years (IQR 1.8, 5.3) at the time of challenge. Sociodemographic characteristics and co-morbidities as well as personal and familial history of atopy were similar between respondents and nonrespondents to follow-up and also between those that reacted and those that tolerated amoxicillin treatment (Table 8 ). All subsequent reactions presented as hives and 85.7 % (95 % CI 42.0, 99.2 %) developed in the first 3 days of treatment.
Conclusion:
The risk of a subsequent reaction among those with a negative challenge is almost 10 %. All reactions were limited to the skin, but some of the reported skin reactions may have been triggered by viral infections and hence the risk may be an overestimate. Clinicians can rely on oral challenges to safely assess true allergy among children with suspected skin-related reactions to amoxicillin. Background: 10 % of people claim to have a penicillin allergy. Verifying a penicillin allergy is important because it reduces patient exposure to other antibiotics that can be associated with increased patient morbidity and healthcare costs. The aim of this study is to report the validity of self-reported penicillin allergies in patients presenting to an allergy clinic. Methods: Retrospective chart review of 284 patients who presented to an allergy clinic between April 2011 to December 2014 for penicillin allergy assessment. Patients had undergone skin, intradermal testing of penicillin and a 5-day oral dose challenge of amoxicillin. Patients whose reactions were negative to skin and intradermal testing went on to receive a 5-day oral dose challenge of amoxicillin. Patients with history of serum sickness or Steven-Johnson syndrome/TENS were excluded from this clinic. Results: 8.1 % (23 of 284) of self-reported penicillin allergies were found to be truly allergic as determined by either skin test, intradermal test or 5-day oral challenge. There were 6 reactions to skin and intradermal testing, and these patients did not go on to receive oral doses of amoxicillin. Of those who received the oral challenge, a small number of patients (5 of 284) reacted within 24 h of ingestion of the first dose of amoxicillin. A majority of patients (12 of 284) had a delayed reaction with a rash occurring 24 h after initial ingestion penicillin. Of the oral challenges, the reactions included 6 with hives and 11 with a rash. No oral challenge resulted in cardiopulmonary compromise.
A34
Validity of self-reported penicillin allergies
Conclusions:
Of those reporting a penicillin allergy, only 8.1 % were proven to have a reaction. Of these, the majority had a delayed reaction to penicillin, which typically only involved a rash. There were no life-threatening reactions. Penicillin allergy testing can determine whether patients should actually be avoiding penicillin. Background: Currently there is no consensus on the optimal treatment of eosinophilic esophagitis (EoE). One of the options, an elimination diet guided by allergy test results, has been shown to be effective to varying degrees with greater efficacy in pediatric cohorts [1, 2] . However, results in adults have been less promising as higher rates of negative allergy tests hinder efforts to guide the diet [3] . This study explores the results of allergy-test directed elimination diets in a group of patients (n = 16) treated at the Allergy and Immunology Clinic in London, Ontario. Methods: A retrospective chart review was performed using a database of patients diagnosed with EoE (histology ≥ 15 eo/hpf in esophageal biopsy) and treated at the Allergy and Immunology Clinic at St. Joseph's Hospital, London, ON. Patients were included in the review if they had been prescribed an elimination diet guided by allergy testing [skin-prick test (SPT) and/or atopy patch test (APT)], and had esophageal biopsies taken ≥ 8 weeks after initiation of the diet. Pre-treatment eosinophil counts were recorded from peak eosinophil counts of the most recent biopsy prior to initiation of the elimination diet. Results: The average age of subjects at diet initiation was 43.75 years (see Table 9 for subject demographics). On average, each subject eliminated 1.7 foods from their diet. Post-diet biopsies displayed a significantly lower level of peak eosinophils/hpf compared to pre-diet biopsies on average (37.9 vs. 89.8, p = 0.043; Fig. 4) . Three patients had post-diet biopsies below the histological threshold of diagnosis for EoE (<15 eo/hpf ).
A35
Effectiveness of allergy-test directed elimination diets in eosinophilic esophagitis
Conclusions: This chart review shows that patients undergoing elimination diets directed by allergy tests have significant histological improvement after their diets. It must be noted that this review did not control for the effects of confounding treatments such as PPIs and corticosteroids, with the latter being of greater concern to histological results. Half of the subjects examined (8 out of 16) had been, at some time before the post-diet biopsy, prescribed swallowed corticosteroids for EoE. However, only 1/4 of steroid-prescribed subjects reported using the steroids during the 30-day period immediately prior to their post-diet biopsy. Background: Foods are a major trigger for eosinophilic esophagitis (EoE) in children; however, the optimal method for identifying the causative foods is unclear. We investigated the role of allergy testing in a pediatric tertiary centre and its use in identifying causative foods in children with biopsy-confirmed EoE. Methods: A retrospective analysis of all children diagnosed with EoE by a pediatric gastroenterologist from January 2004 to September 2014 was completed. All patients met criteria for diagnosis defined by symptoms of esophageal dysfunction and biopsy-proven eosinophilia with greater than 15 eosinophils per high-power field (hpf ). Results: Ninety-eight (98) children were included (average age 10.4 years, 77 % male, and 61 % atopic). Presenting symptoms included dysphagia (52 %), abdominal pain (38 %), and GERD (35 %). 69 patients were assessed by an allergist, 62 had skin prick testing (SPT) to foods; 40 were positive, most commonly to egg, soy, peanut and rice. 50 had atopy patch testing (APT); 26 were positive, most commonly to chicken, egg, wheat and corn. 46 patients underwent dietary intervention as part of their management, with 27 patients (57 %) reporting symptom improvement. 14 patients had follow-up endoscopy and nine had documented histologic improvement. With dietary interventions, the average number of foods avoided was 2.7.
Conclusions: Approximately half of the EoE patients undergoing dietary modifications based on allergy testing reported symptom improvement. When compared to the Six-Food Elimination Diet (SFED), patients avoided on average fewer foods. A stagedapproach using SPT and APT followed by SFED may be an option for some patients, with the advantage of potentially avoiding less foods. This benefit needs to be balanced against the time required for allergy testing. Further studies comparing the feasibility of these two dietary approaches in the management of EoE in children are needed.
A37
Visualizing the impact of atopic and allergic skin disease Dominik A. Nowak Background: Cutaneous disease is known to impact psychosocial wellbeing. This sentiment is especially true in the chronic inflammatory dermatoses such as atopic dermatitis and idiopathic urticaria. Degree of itch plays a role, as do age and socioeconomic status. There is poor correlation, nonetheless, between severity and impact of skin disease, and physicians are themselves poor at gauging the psychosocial impact of skin problems [1] . We set out to visualize this impact by means of a word cloud.
Methods:
Participants answered the open-ended question "How has your skin affected you (e.g. your mood, self-image, relationships, discomfort)?" Responses were transcribed into the word cloud software Wordle [http://www.wordle.net].
Results: Eighty responses were recorded, with a mean age of 44 and a mean word count of 20. Twenty-five of 80 participants screened positive for depression by scoring three or above on the two-item PHQ-2 tool. Seven of eight participants whose complaints included the atopic or allergic screened positive-these included patients with atopic dermatitis, idiopathic urticaria, hand eczema, and allergic contact dermatitis. More frequent phrases were given a proportionally larger size in the graphic. Figure 5 visualizes the answers provided by the eight atopic and allergic patients.
Conclusions:
Clinicians cannot overlook psychosocial wellbeing in skin disease. Specialists pressed for time may consider aligning themselves with a skin-emotion expert, be it a social worker or psychiatrist [2] .
A38
Cystic fibrosis with and without nasal polyposis in pediatric patients: a cross-sectional comparative study Mihaela Paina Background: Sinonasal disease is often diagnosed in patients with cystic fibrosis (CF). Some studies suggest that CF patients with nasal polyps have less severe pulmonary disease and overall improved survival. Our study examines factors associated with nasal polyposis in pediatric CF patients. Methods: Cross-sectional study of 26 CF patients (2008) (2009) (2010) (2011) . Nasal polyps were diagnosed by anterior rhinoscopy. The study group (n = 16, 61.5 %): CF patients with nasal polyposis. The comparison group (n = 10, 38.5 %): CF patients without nasal polyposis. Clinical/biochemical data were gathered. Pulmonary function test, skin prick test, sputum/throat culture, nasal lavage and genotype analysis were performed. Minitab (t test, Chi square test) and a p value of < 0.05 were used for statistical analysis and significance, respectively. Results: CF patients with nasal polyps are more likely to have Aspergillus serum precipitins (50 vs 10 %, p = 0.02). Positive allergy skin prick tests are common (50 vs 70 %, p = 0.29). Atopy to Aspergillus fumigatus is most prevalent in the nasal polyposis group (62.5 vs 42.85 %, p = 0.29). Other appreciable characteristics of this group are: better nutritional status (mean BMI 20.7 vs 18.7 kg/m 2 , p = 0.06), ΔF508 homozygosity (68.7 vs 40 %, p = 0.13), suboptimal vitamin D levels in winter (83.3 vs 50 %, p = 0.14) and better pulmonary function (mean FEV1 % predicted 82 vs. 78, p = 0.4). Staphylococcus aureus is the most common pathogen in the sputum/throat cultures and neutrophils are prevalent in all nasal lavage samples, with no difference between the groups. Conclusions: Patients with CF and nasal polyposis may constitute a clinical subgroup within the spectrum of the disease. These patients appear to have a higher exposure to Aspergillus. This, together with the higher prevalence of atopy to Aspergillus, may suggest an association with nasal polyposis. Also more likely are: ΔF508/ΔF508 genotype, better pulmonary function/nutritional status, and lower vitamin D levels in winter. Our results confirm and complement those of previous studies. Acknowledgements: This research study received funding from the Ontario Thoracic Society (Block Term Grant).
A39
Evaluation of macrolide antibiotic hypersensitivity: the role of oral challenges in children Bahar Torabi are diagnosed without further evaluation and are labelled as allergic to the implicated antibiotic. There is sparse data regarding the percentage of established macrolide allergy among children who present with suspected macrolide hypersensitivity. Furthermore, there are no standardized skin tests to confirm the presence of macrolide hypersensitivity [2] . Our objective was to assess the risk of a hypersensitivity reaction through the use of a graded oral challenge in patients with a suspected macrolide allergy. Methods: As part of the LAACTAM (β-LActam and other Antibiotics allergy in Children: Tests, assessment and Management) study, children presenting to the allergy clinic at the Montreal Children's Hospital for the assessment of a potential macrolide antibiotic allergy were recruited. Data on demographics and reaction characteristics was collected through a standardized questionnaire. Patients underwent a graded challenge (10 and 90 % of the dose) of either azithromycin or clarithromycin, and were observed for 1 h after the last dose. In addition, patients were contacted every 12 months to query on potential non-immediate reactions or reactions on subsequent use. Results: Fifty-one subjects with a macrolide allergy were recruited. 80.4 % (95 % CI 66.5, 89.7 %) had reported a reaction to clarithromycin and 19.6 % (95 % CI 10.3, 33.5 %) to azithromycin. The majority of reactions were isolated to the skin and occurred within the first 3 days of the antibiotic course (Table 10 ). Three subjects out of 51 (5.9 % [95 % CI 1.5, 17.2 %]) had a positive graded challenge. All three reactions were limited to the skin and occurred within the first hour of observation. No late reactions were documented and none of the patients reported repeated use of the culprit macrolide.
Conclusion:
The risk of a reaction in children with a history of a macrolide hypersensitivity is low and seems to occur within 1 h of the oral challenge. Currently an oral provocation is the best tool in diagnosing a macrolide allergy. Larger studies are needed to support these findings and identify risk factors associated with positive challenges. Background: Many institutions recommend a stepwise approach to intradermal testing for venom allergy [1] . This is costly and uncomfortable for the patient. The rational for this approach is the risk of potential adverse reactions to testing with the maximal dose alone. Strohmeier et al. [2] recently described the safety of a simultaneous approach to testing different venom concentrations, and Yocum has previously described the safety of a two-step approach to testing [3] . Our objective of this study was to evaluate the safety of a single step approach to venom allergy testing. Methods: We retrospectively reviewed charts of 300 consecutive patients with suspected hymenoptera venom allergy based on history that underwent venom allergy testing in a single allergist's clinic where a single step protocol had been adopted. Charts were reviewed for patient characteristics including medications, testing protocol used, results of testing, and reported immediate and delayed adverse reactions to testing. Results: All patients underwent testing with an identical single-step protocol with an intradermal dose of 0.02 mL of a 1.0 μg/mL concentration of each of the five commercially available vespid and bee venoms. Patients ranged from 4 to 83 years of age. Only one patient reported an adverse reaction to testing, which was delayed until the morning following his visit. There were no immediate adverse reactions. This patient was successfully started on venom immunotherapy subsequent to his reaction. Conclusion: A single step venom allergy intradermal testing protocol with a 1.0 μg/mL concentration of commercially available extracts is a safe option, which, if adopted into practice, would potentially lead to more streamlined care for patients and cost savings for the medical system.
Background:
Characterizing reactions and assessing the safety of future cephalosporin administration in children is important, given the critical role these antibiotics play in the empirical treatment of serious infections. Because skin tests to cephalosporins remain to be validated [1] , we aimed to evaluate the usefulness of oral challenges in assessing the risk of future reaction to these drugs. Methods: Children presenting to drug allergy clinics at the Montreal Children's Hospital during a consecutive 3-year period starting in March 2012, with a history of suspected hypersensitivity to cephalosporins, received graded oral challenges (10 %, followed by the remaining 90 % 
Conclusion:
The risk of reaction is low in children with a history of suspected hypersensitivity to cephalosporins. Oral challenges appear to be safe in this population, and may be the best tool available to diagnose cephalosporin hypersensitivity. Larger studies are needed to support these results.
Background:
The impact of breastfeeding on asthma and allergy development is controversial. We aimed to characterize the association of breastfeeding with childhood wheeze, atopy and atopic dermatitis in the first year of life.
Methods:
We studied 2587 infants with complete breastfeeding data from the Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort. Infant diet and wheezing episodes were reported by mothers at 3, 6, and 12 months. Atopy was determined by skin testing and atopic dermatitis was diagnosed at 12 months. Breastfeeding was classified as exclusive (human milk only), partial (supplemented with formula, other beverages or solid foods) or none. Results: Breastfeeding rates were 82 % at 3 months (52 % exclusive, 30 % partial), 74 % at 6 months (13 % exclusive, 61 % partial), and 46 % at 12 months (partial). In their first year, 21 % of infants experienced ≥ 1 wheezing episode, 14 % were sensitized to ≥1 allergen, and 12 % were diagnosed with atopic dermatitis. Breastfeeding rates were lower among younger mothers, First Nations women, and those who smoked or did not have a postsecondary degree. Independent of these maternal characteristics, increasing duration and intensity of breastfeeding were associated with a reduced risk of wheezing: adjusted odds ratio (aOR) 0. Background: Inflammation is a key mechanism of asthma pathogenesis [1] . The bronchial epithelium acts as a barrier involved in innate and adaptive immunity through secretion of inflammatory mediators [2] . Interleukin (IL) 33 is an alarmin cytokine released by airway epithelial cells [3] that has been identified as a gene of susceptibility in asthma in several studies [4] [5] [6] , as well as being a potential severity biomarker of asthma [7] . IL33 gene expression was increased in epithelial cells from asthmatic individuals [8] . However, less is known about the epigenetic regulation of IL33 particularly in severe asthma. In this context, we aimed to characterize DNA methylation (DNA-me) and expression signatures of IL33 in epithelial cells obtained from mild and severe asthmatic individuals. Methods: A total of 21 bronchial epithelial cell (BEC) lines from asthmatics individuals (mild n = 7; severe n = 4) and control individuals (n = 10) were used for DNA and mRNA extraction. DNA-me was measured by bis-pyrosequencing and mRNA level was assessed by qRT-PCR. Student t tests were performed to analyze the association between DNA-me and asthma severity (significant for Δβ > 5 % and p > 0.05).
Pearson correlations were used to analyze the correlation between DNA-me and mRNA level. Results: A hypomethylation for mild and severe BEC groups (Δβ = 22 %, p = 0.003; Δβ = 17 %, p = 0.090 respectively) was observed. The DNA-me of IL33 promoter was also negatively correlated with mRNA levels (r = −0.750, p = 0.050), suggesting an upregulation of gene expression by DNA-me. The total mRNA level for IL33 was increased in BECs from mild and severe asthmatic individuals (foldchange = 3.4, p = 0.017; foldchange = 4.7, p = 0.060 respectively). Background: Bronchial epithelial cells play an important role in mediating the response to airway injury and repair through the release of chemotactic factors, such as interleukin 8 (IL-8) and antioxidant production. These antioxidant mechanisms are particularly important in the context of neutrophil-mediated pulmonary disease. Inhalation of organic dust (OD) from swine confinement facilities leads to pulmonary neutrophilia, airway hyperresponsiveness and oxidative stress. We sought to examine the role of NRF2, a critical transcription factor involved in mediating the endogenous antioxidant response, in bronchial epithelial cells following OD exposure. We hypothesized that OD exposure would increase NRF2 activity and antioxidant production in human bronchial epithelial cells. Methods: A human bronchial epithelial cell line (BEAS-2B) was stimulated for 24 h with 100 µg OD. Supernatant was retained for evaluation of IL-8 by ELISA. qPCR was performed for NRF2-dependent and NRF2-independent antioxidant genes. NRF2 nuclear translocation was quantified at various time points using an NRF2 luciferase reporter assay and by immunofluorescence. Results: OD exposure resulted in an increase of IL-8 release. mRNA expression levels of NRF2-dependent antioxidant genes HO-1, NQO1 and GCLM, but not of NRF2-independent antioxidant genes SOD 1, and catalase were increased following OD exposure compared to control cells. OD exposure induced a time and dose-dependent increase in luminescence indicating NRF2 nuclear translocation, a result confirmed by quantification of NRF2 nuclear localization by immunofluoresence. Conclusions: OD exposure induces IL-8 release, NRF2 nuclear translocation, and upregulation of antioxidant gene expression in BEAS-2B cells. These results suggest a dual role for bronchial epithelial cells in mediating neutrophil recruitment as the endogenous antioxidant response. We demonstrated that the endogenous oxidative properties of OD are specific to NRF2 and that NRF2 is a critical mediator of ODinduced oxidative stress in bronchial epithelial cells.
A45
The effects of perinatal distress, immune biomarkers and mother-infant interaction quality on childhood atopic dermatitis (rash) at 18 months Nela Cosic Background: Perinatal psychosocial distress, including stressful life events, anxiety and depression are risk factors for childhood atopic dermatitis (rash) [1] . Maternal psychosocial distress is associated with excess prenatal stress hormones [2] and reduction in the quality of maternal-infant interaction [3] , which may affect biomarkers of infant immunity such as interleukin (IL) levels and predispose the growing child to rash [4, 5] . This study will: (1) describe the association between perinatal distress and infant interleukins at 3 months of age, (2) describe the association of interleukins and atopic dermatitis (rash), and (3) build a best fit model from the identified associations in (1) and (2) . Methods: 120 women reported distress levels during pregnancy and at 3 months postpartum. Venous blood was collected from their 3-month-old infants to assess plasma interleukin levels. Maternal-child interaction was measured 6 months postpartum with the nursing child assessment teaching scale. Presence and number of skin areas affected by rash were assessed via parent report at 18 months. Correlation and multiple regression analyses identified the best fit model for rash using forward stepwise regression. Results: Prenatal depression (r = −0.23, p = 0.01) and stressful life events pre-and post-natally (r = 0.27, p = 0.00) were associated with IL2p70. Pre-and post-natal anxiety were associated with IL8 (r = −0.28, p = 0.02) and IL4 (r = −0.24, p = 0.04). IL10 was associated with child skin rash (r = −0.25, p = 0.01) at 18 months. 20 % of the variance in childhood rash at 18 months was explained by the model (Table 11) . Conclusions: Perinatal distress is associated with elevated infant ILs. Demographic variables (maternal age, education), IL10, perinatal stressful life events (e.g. separation/divorce, family death) and maternal-infant interaction best predicted skin rash in 18-month-old infants. We will now evaluate how maternal-child interaction moderates associations between both (1) perinatal distress and (2) immune biomarkers, and atopic dermatitis in children at 18 months. Background: The study aimed to evaluate tryptase levels in children presenting with anaphylaxis, to examine predictors of elevated tryptase (defined as levels ≥11.4 ng/mL), and to compare tryptase levels during and post-anaphylaxis.
Methods:
Between April 2011 and September 2014, data were collected on anaphylaxis cases at the Montreal Children's Hospital Emergency Department. Cases were recruited either prospectively or identified retrospectively through chart review. Total tryptase levels were measured within 2 h following onset of symptoms. Levels during reaction and approximately 10 months after reaction were compared using confidence intervals based on paired means using the t distribution. Logistic and linear regression models were fit to estimate the associations between tryptase levels and sociodemographic and clinical characteristics of anaphylaxis.
Results: Over a three-year period, 165 children were recruited and had serum tryptase levels measured. Among those, the mean tryptase level was 7.6 μg/l (SD 6.4) and 32 cases [19.4 % (95 % CI, 13.8, 26.4 %)] had elevated tryptase levels. Elevated levels were found more frequently in severe reactions compared to moderate and mild reactions (Table 12) . Of the 54 children with post-reaction tryptase levels, the mean tryptase level was 8.2 μg/l during reaction and 3.7 μg/l post-reaction; yielding a difference of 3. 
, Chris Carlsten
Background: Asthma is a chronic inflammatory disease of the airways. Diesel exhaust (DE) is a major contributor to ambient particulate matter (PM). There is evidence that PM acts as an adjuvant to biological allergens and aggravates allergic inflammation [1, 2] . We aim to elucidate if DE increases allergen-induced inflammation and cellular immune response in the airways of atopic human subjects. Methods: We recruited 12 volunteer subjects with allergy to house dust mite (HDM), birch or timothy grass. In a randomized blinded, crossover design, subjects were exposed to DE (300 µg PM 2.5 /m 3 ) or filtered air for 2 h. One hour following the exposure, segmental allergen challenge was performed by instilling into contralateral lung segments through flexible bronchoscopy, either the allergen extract to which the participant is sensitive to, or placebo (sterile saline). Endobronchial biopsies from the same segments were then obtained 48 h Background: Allergic diseases are the earliest of all chronic diseases to develop in children and their prevalence is on the rise [1, 2] . Skin prick tests (SPT) are considered an important diagnostic tool for allergies [3, 4] . SPT results to a specific allergen are typically calculated by manual measurement of the wheal of a response. The objective of this study is to evaluate a new, automated, image-processing method for wheal measurements against the standard of manual measurements. The Canadian Healthy Infant Longitudinal Development (CHILD) Study is a general population, longitudinal study that focuses on the development of allergy in early life. For the purposes of this project, we measured SPTs from one-year clinic visits at the Manitoba CHILD site. SPTs were performed for common allergens as well as positive and negative controls, histamine and glycerine respectively. Methods: SPTs were performed for 10 common allergens (cat, dog, cockroach, D. farinae, D. pteronyssinus, Alternaria, cow's milk, egg white, soybean and peanut) and controls in 1033 children (mean age 13 ± 2 months). Of the 12,396 tests, there were measurable wheals for 1180 SPTs, identified by both automated and manual methods. By manual measurements 1105 wheals were ≥2 mm while by the automated method 1004 were ≥2 mm. Each child's results were measured by hand and by an automated scan and measure system developed in our laboratory. The overall diameters averaged 2.94 ± 1.0 (range 0.5-7.8) by the automated method and 3.52 ± 1.1 (range 0.5-9.3) by the manual method with a correlation coefficient of 0.91.
Results:
The results demonstrate the value of the automated measurements. The potential advantages of the automated method are reproducibility, accuracy, and speed when compared with manual measurements.
assessed by Nasal Allergen Challenge (NAC) [3] . Whole blood was collected into PAXgene tubes at baseline and post NAC (1, 2, and 6 h), before and 1 month post treatment. 770 immune genes in the PAXgene blood lysates at 6 h post NAC were profiled using the nanoString nCounter PanCancer Immune Profiling Panel. After normalization, a statistical comparison of pre-versus post-treatment changes was performed and an enrichment pathway analysis undertaken (Enrichr). Results: 70 immune genes were significantly down regulated compared to pre-treatment at the 6 h post NAC time point (FDR < 10 %). These genes were associated with T-cell effector pathways, particularly canonical Th2 cytokines such as IL-4, IL-5, IL-3, IL-6 and TSLP. These changes were accompanied by significant post-versus pre-treatment reductions in clinical symptoms, Total Nasal Symptom Score and Peak Nasal Inspiratory Flow. Conclusion: Following Cat-SPIRE treatment, systemic immune pathways of T-cell effectors were changed in peripheral blood of cat exposed, allergic individuals. The effect on these pathways provides insight towards the mechanism by which Cat-SPIRE induces immune tolerance. Whole blood immune transcriptome profiling in larger sample sizes and/or various time points after NAC may provide biomarkers or tools to discover the immune response or tolerance mechanism.
Background: Children of low-income families access more urgent care and less preventive care for asthma [1] . Children with a respiratory disease from low-income families also experience a lower quality of life [2, 3] . Our previous online peer/professional support programs have improved children's asthma and allergy self-management skills, and decreased loneliness [4] [5] [6] [7] [8] . However, in our previous programs, participants' have come from high-income families [4] [5] [6] [7] [8] . Consequently, the objective of this research was to determine low-income participants' perceptions of the impact of the support intervention, the factors influencing these impacts, their satisfaction with the intervention, and recommended changes. Methods: Peer and professional mentors who lived with asthma and allergies and had experience with vulnerable families were recruited and trained to facilitate sessions. Participants in the cohort included 16 children aged 7-11, and adolescents 12-17 from across Canada. Children were provided with internet services for the program duration, chromebooks, and headsets/microphones that they could keep. Eight weekly meetings were offered on the Internet using GoToMeeting ® ; a secure online meeting platform. Quantitative data on health-related outcomes were elicited by standardized measures administered preand post-intervention. Qualitative data on the intervention processes was also collected. Results: Preliminary analysis post-intervention, has shown an increase in coping skills and perceived support, and reduced loneliness after participating in the online sessions. Even more significant, in comparison to online programs with higher income families, was the increased understanding and appreciation of asthma/allergy triggers in participants. They also learned new ways to manage their triggers. Many parents reported that their children were less resistant to taking their medication and had a higher adherence to medication post-intervention due to an increased understanding about their medications and use. Conclusion: It is evident that online-peer-support programs for lower income families require a different focus compared to programs developed for higher income families, as they face different challenges and have different needs. Background: Asthma is a chronic respiratory disease involving genetic and environmental interactions [1, 2] . More than 300 genes have been associated with asthma or related phenotypes, and the number continues to increase [3] . The associated common SNPs represent a small part of the genetic component and the exact nature of the causal genetic variants remains to be discovered [4] . One reason for this "missing heritability" is that many genetic factors act primarily through complex mechanisms involving interactions with other genes and environmental factors and/or epigenetic mechanisms [5] . We have shown that genetic variants related to asthma can be mechanistically studied using epigenetic and functional genomic assessment of individual variants [6, 7] . Therefore, we plan to focus on IL33 pathway following the previous study demonstrating a correlation between methylation signature, expression and asthma in bronchial epithelial cells. Method: DNA methylation (Δβ) has been measured with an epigenome wide association study (EWAS) using Illumina Allergy Asthma Clin Immunol 2016, 12(Suppl 1):22 HumanMethylation450K arrays among 69 asthmatic individuals and 91 controls. Data were extracted for 21,720 genes including 26 in the pathway of IL33 and the association with asthma was assessed by logistic regression using methylation percentage, asthma phenotype, sex, age, IgE level, smoking status and eosinophils, lymphocytes, monocytes, neutrophils, and basophils counts as covariates. Batch effect was corrected for the analysis. Results: A total of four genes have demonstrated a significant difference of methylation between asthmatic individuals and control ones: CLSTN2 (Δβ = 7.35 %, p = 0.0008), CDSN (Δβ = 7.39 %, p = 0.02), PSORS1C1 (Δβ = 7.39 %, p = 0.02) and CCDC57 (Δβ = 5.63 %, p = 0.02). Conclusion: This study shows differences in methylation marks between asthmatic individuals and non-asthmatic non-allergic controls for four genes (CLSTN2, CDSN, PSORS1C1, CCDC57) . Interestingly, PSORS1C1, a susceptibility gene for psoriasis, has already been associated with asthma in a genome wide association study in Latino children [8] . The pyrosequencing of this gene will allow us to confirm this association. Background: Sterile inflammation is a major mechanism by which tissue damage occurs throughout the body and is also a major determinant of disease progression. It is initiated after sterile physical damage has occurred in local tissues, but can also be initiated in a number of inflammatory disorders, such as asthma and arthritis. Many different cell types appear to be involved in sterile inflammation, but the role of mast cells has been of particular interest. Mast cells are innate immune sentinel cells that reside in many tissues throughout the body that synthesize and secrete many pro-and anti-inflammatory mediators. The alarmin IL-33 is an important component of the sterile inflammatory process and has been shown to directly activate populations of mast cells [1, 2] . Furthermore, IL-33 has been implicated as a potential early-life predictor of childhood asthma and allergy [3] . Therefore, the purpose of this study was to determine the cytokine and chemokine profile of human mast cells activated with IL-33. Methods: Cord blood-derived mast cells (CBMCs) were activated for 24 h with IL-33 at a concentration of 30 ng/mL. To analyse protein production from CBMCs, supernatants were collected and a Luminex assay was conducted to analyse the concentration of 29 cytokines and chemokines. Additionally, gene expression data was analyzed through qPCR to determine gene expression changes upon activation of mast cells with IL-33. Results: It was found that after IL-33 activation, CBMCs had a statistically significant increase in production of IL-13, but not other T H 2-related cytokines such as IL-4. There was no increase in production of T H 1-related cytokines, such as IFNγ and IL-12. Production of the cytokines VEGF and GM-CSF were also statistically significantly increased after IL-33 activation of CBMCs. Conclusions: In conclusion, IL-33 activation of human mast cells results in the production of cytokines supportive of T H 2-driven responses and tissue regeneration. Fig. 7 CMP-specific IgA to casein (a) and ALA (c) increased significantly from pre-therapy to 300 mL challenge with CM (unpaired t test, **P < 0.01 and *P < 0.05 respectively for casein and ALA). Casein (d), BLG (e), and ALA (f) specific IgG4 increased significantly baseline at the completion of OIT (unpaired t test, *p < 0.05, ***p < 0.001, ***p < 0.001 respectively for casein, BLG, and ALA)
